KRAS和BRCA1/2基因突变状态对卵巢上皮癌患者预后的影响

The effect of KRASand BRCA1/2 gene mutation status on the prognosis of patients with epithelial ovarian cancer

目的探讨KRAS和BRCA1/2基因突变状态对评估卵巢上皮癌患者预后的临床价值。方法基因测序分析KRAS和BRCA1/2基因的多态性,采用Cox比例风险回归模型和Kaplan Meier生存分析法进行分析KRAS和BRCA1/2基因突变状态与化疗疗效及预后的相关性。结果 KRAS基因多态性与顺铂+紫杉醇化疗敏感性无相关性,对患者的无进展生存期及总生存期并不产生影响;与野生型BRCA2基因携带患者相比,BRCA1/2基因突变患者对顺铂+紫杉醇化疗相对较好的反应性,有望获得相对较好的生存期。结论BRCA1/2基因突变状态预示对顺铂+紫杉醇化疗相对敏感,患者能获得相对较好的生存期,BRCA1/2基因有可能作为一种生物标记物指导卵巢上皮癌的个性化化疗。

[Objective ] To investigate the clinic;d valueof KRAS and BRCA1/2 gene mutation status in assessing the prognosis of patients with epithelial ovarian cancer. [Methods] The polymorphism of KRAS and BRCA1/2 gene sequencing was studied using Cox proportional hazards regression model and Kaplan Meier survival analysis method was used to analyzethe correlation between KRAS and BRCA1/2 gene mutation status and chemotherapy efficacy and prognosis. [ Results ] There was no correlatior between the KRAS gene polymorphism and susceptibility to cis- platin plus paclitaxel chemotherapy, which did not affect the progression free survival and overall survival of pa- tients; Compared with the wild type BRCA2 gene patients carried, BRCA1/2 gene mutation in patients with cisplatin plus paclitaxel chemotherapy were in relatively good re-activity, who was expected to be relatively good survival. [Conclusion] BRCA1/2 gene mutations that are relatively sensitive to cisplatin plus paclitaxel chemotherapy, pa- tients can get relatively good survival, BRCA1/2 gene may serve as a biomarker for individualized chemotherapy guidance of epithelial ovarian cancer.